Literature DB >> 2418846

Effects of the benzimidazole derivatives pimobendan and 2-(4-hydroxy-phenyl)-5-(5-methyl-3-oxo-4,5-dihydro-2H-6- pyridazinyl) benzimidazole . HCl on phosphodiesterase activity and force of contraction in guinea-pig hearts.

C Berger, W Meyer, H Scholz, J Starbatty.   

Abstract

The effects of pimobendan (UD-CG 115 BS) and UD-CG 212 Cl (2-(4-hydroxy-phenyl)-5-(5-methyl-3-oxo-4,5-dihydro-2H-6- pyridazinyl)benzimidazole X HCl) on force of contraction, beating frequency, and on adenylate cyclase and phosphodiesterase activity were investigated in isolated preparations from guinea-pig hearts. Both benzimidazole derivatives exerted a concentration-dependent positive inotropic effect in guinea-pig papillary muscles. The efficacies were similar to that of dihydroouabain. The positive inotropic effect of both benzimidazoles was accompanied by an enhancement of the rate of force development and a prolongation of the contraction. Both benzimidazole derivatives inhibited phosphodiesterase (PDE) activity in a crude preparation from guinea-pig ventricles. However, at the concentrations producing maximal positive inotropic effects in papillary muscles, pimobendan and UD-CG 212 Cl diminished PDE activity only by about 20-30%. Since both benzimidazoles did not affect adenylate cyclase in a particulate membrane preparation a stimulation of the cAMP synthesis can be ruled out. As recently reported for pimobendan, this study provides functional evidence that the positive inotropic effect of UD-CG 212 Cl is also at least partially mediated by cAMP. Firstly, the positive inotropic effect of UD-CG 212 Cl was inhibited by carbachol, adenosine and (-)-N6-phenyl-isopropyladenosine. Secondly, UD-CG 212 Cl potentiated the inotropic effects of isoprenaline and histamine. UD-CG 212 Cl had no positive chronotropic effect and pimobendan increased the beating frequency only slightly.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2418846

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  14 in total

1.  Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.

Authors:  H von der Leyen; U Mende; W Meyer; J Neumann; M Nose; W Schmitz; H Scholz; J Starbatty; B Stein; H Wenzlaff
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-07       Impact factor: 3.000

Review 2.  New mechanisms for positive inotropic agents: focus on the discovery and development of imazodan.

Authors:  R E Weishaar; D Kobylarz-Singer; B A Klinkefus
Journal:  Cardiovasc Drugs Ther       Date:  1989-03       Impact factor: 3.727

3.  Influence of the calcium-sensitizer UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. Comparison with nitroprusside.

Authors:  G Hasenfuss; C Holubarsch; H W Heiss; B Rattert; H Just
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

4.  Pharmacokinetic profile and tolerability of pimobendan in patients with terminal renal insufficiency.

Authors:  M Przechera; W Roth; V Kühlkamp; T Risler; M Haehl
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 5.  Phosphodiesterase inhibition by new cardiotonic agents: mechanism of action and possible clinical relevance in the therapy of congestive heart failure.

Authors:  H von der Leyen
Journal:  Klin Wochenschr       Date:  1989-06-15

6.  The positive inotropic response to milrinone in isolated human and guinea pig myocardium.

Authors:  L Brown; M Näbauer; E Erdmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-10       Impact factor: 3.000

Review 7.  Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.

Authors:  A Fitton; R N Brogden
Journal:  Drugs Aging       Date:  1994-05       Impact factor: 3.923

8.  Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure.

Authors:  S Sasayama; H Asanoi; Y Kihara; S Yokawa; Y Terada; S Yoshida; M Ejiri; I Horikoshi
Journal:  Heart Vessels       Date:  1994       Impact factor: 2.037

9.  Cyclic AMP-dependent and cyclic AMP-independent actions of a novel cardiotonic agent, OPC-8212.

Authors:  S T Rapundalo; D A Lathrop; S A Harrison; J A Beavo; A Schwartz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-12       Impact factor: 3.000

10.  Systemic haemodynamic actions of pimobendan (UD-CG 115 BS) and its O-demethylmetabolite UD-CG 212 Cl in the conscious pig.

Authors:  D J Duncker; J M Hartog; L Levinsky; P D Verdouw
Journal:  Br J Pharmacol       Date:  1987-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.